REST Final-Exon-Truncating Mutations Cause Hereditary Gingival Fibromatosis

dc.contributor.authorBayram, Yavuz
dc.contributor.authorWhite, Janson J.
dc.contributor.authorElcioglu, Nursel
dc.contributor.authorCho, Megan T.
dc.contributor.authorZadeh, Neda
dc.contributor.authorGedikbasi, Asuman
dc.contributor.authorLupski, James R.
dc.date.accessioned2026-02-06T18:36:17Z
dc.date.issued2017
dc.departmentDoğu Akdeniz Üniversitesi
dc.description.abstractHereditary gingival fibromatosis (HGF) is the most common genetic form of gingival fibromatosis that develops as a slowly progressive, benign, localized or generalized enlargement of keratinized gingiva. HGF is a genetically heterogeneous disorder and can be transmitted either as an autosomal-dominant or autosomal-recessive trait or appear sporadically. To date, four loci (2p22.1, 2p23.3-p22.3, 5q13-q22, and 11p15) have been mapped to autosomes and one gene (SOS1) has been associated with the HGF trait observed to segregate in a dominant inheritance pattern. Here we report 11 individuals with HGF from three unrelated families. Whole-exome sequencing (WES) revealed three different truncating mutations including two frameshifts and one nonsense variant in RE1-silencing transcription factor (REST) in the probands from all families and further genetic and genomic analyses confirmed the WES-identified findings. REST is a transcriptional repressor that is expressed throughout the body; it has different roles in different cellular contexts, such as oncogenic and tumor-suppressor functions and hematopoietic and cardiac differentiation. Here we show the consequences of germline final-exontruncating mutations in REST for organismal development and the association with the HGF phenotype.
dc.description.sponsorshipNational Human Genome Research Institute (NHGRI); National Heart Lung and Blood Institute (NHBLI) [UM1 HG006542]; NHGRI [U54HG003273]; National Institute of Neurological Disorders and Stroke (NINDS) [R01NS05829]; NHGRI of the United States NIH; NHBLI of the United States NIH; NINDS of the United States NIH; Regeneron Pharmaceuticals
dc.description.sponsorshipWe thank the families for participation in this study. This work was supported in part by funding from the National Human Genome Research Institute (NHGRI) and National Heart Lung and Blood Institute (NHBLI) to the Baylor-Hopkins Center for Mendelian Genomics (BHCMG, UM1 HG006542); NHGRI grant to Baylor College of Medicine Human Genome Sequencing Center (U54HG003273), National Institute of Neurological Disorders and Stroke (NINDS) (R01NS05829 to J.R.L.), and NHGRI, NHBLI, and NINDS, all Institutes of the United States NIH. J.R.L. has stock ownership in 23andMe and Lasergen, is a paid consultant for Regeneron Pharmaceuticals, and is a coinventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases, and bacterial genomic fingerprinting. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the chromosomal microarray analysis (CMA) and clinical exome sequencing offered in the Baylor Genetics Laboratory. M.T.C. and A.B. are employees of GeneDx.
dc.identifier.doi10.1016/j.ajhg.2017.06.006
dc.identifier.endpage156
dc.identifier.issn0002-9297
dc.identifier.issn1537-6605
dc.identifier.issue1
dc.identifier.orcid0000-0002-1125-7720
dc.identifier.orcid0000-0002-2778-6803
dc.identifier.pmid28686854
dc.identifier.scopus2-s2.0-85026685904
dc.identifier.scopusqualityQ1
dc.identifier.startpage149
dc.identifier.urihttps://doi.org/10.1016/j.ajhg.2017.06.006
dc.identifier.urihttps://hdl.handle.net/11129/12271
dc.identifier.volume101
dc.identifier.wosWOS:000404886800013
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherCell Press
dc.relation.ispartofAmerican Journal of Human Genetics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20260204
dc.subjectTranscription Factor Rest
dc.subjectRestrictive Silencer Factor
dc.subjectGene-Expression
dc.subjectNeuroendocrine Differentiation
dc.subjectSignaling Pathway
dc.subjectRepressor
dc.subjectCancer
dc.subjectFibroblasts
dc.subjectProtein
dc.subjectTumor
dc.titleREST Final-Exon-Truncating Mutations Cause Hereditary Gingival Fibromatosis
dc.typeArticle

Files